LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 8 von insgesamt 8

Suchoptionen

  1. Artikel ; Online: Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.

    Hassaniazad, Mehdi / Farshidi, Hossein / Gharibzadeh, Abdollah / Bazram, Ali / Khalili, Elham / Noormandi, Afsaneh / Fathalipour, Mohammad

    Journal of medical virology

    2022  Band 94, Heft 7, Seite(n) 3184–3191

    Abstract: Favipiravir (FVP), lopinavir/ritonavir (LPV/RTV), and interferon-beta (INF-beta) are considered as potential treatments for COVID-19. We examined the efficacy and safety of FVP and INF-beta compared to LPV/RTV and INF-beta combinations for the treatment ... ...

    Abstract Favipiravir (FVP), lopinavir/ritonavir (LPV/RTV), and interferon-beta (INF-beta) are considered as potential treatments for COVID-19. We examined the efficacy and safety of FVP and INF-beta compared to LPV/RTV and INF-beta combinations for the treatment of SARS-CoV-2. It was a single-center randomized clinical trial. Eligible patients were randomized to receive FVP plus INF-beta versus LPV/RTV plus INF-beta. The primary endpoint was the viral clearance after seven days of randomization. ICU admission, length of stay (LOS) in hospital, in-hospital mortality, and the incidence of adverse events were also measured. This trial was registered on the Iranian Registry of Clinical Trials (IRCT20200506047323N3). Patients were randomly allocated to the FVP (n = 33) and LPV/RTV (n = 33) groups. The viral clearance on Day seven was not significantly different between the FVP (31.1%) and the LPV/RTV groups (16.1%). The rate of ICU admission and likewise the in-hospital mortality in the FVP group (12.5% and 6.3%, respectively) were similar to the LPV/RTV groups (19.4% and 19.4%, respectively). The median LOS in the hospital was also not different (6.8 days [interquartile range; IQR = 5.0-11.0] in the FVP and (8.0 days [IQR = 5.5-12.5]) in LPV/RTV groups (p = 0.140). Adverse events were observed in 25.0% of FVP and 32.3% of LPV/RTV groups. The combination therapy with FVP did not exert a higher efficacy compared to the combination regimen of LPV/RTV. However, both treatment regimens demonstrated a mild profile of adverse events.
    Mesh-Begriff(e) Amides/therapeutic use ; COVID-19/drug therapy ; Humans ; Interferon-beta/therapeutic use ; Iran ; Lopinavir/therapeutic use ; Pyrazines/therapeutic use ; Ritonavir/therapeutic use ; SARS-CoV-2
    Chemische Substanzen Amides ; Pyrazines ; Lopinavir (2494G1JF75) ; Interferon-beta (77238-31-4) ; favipiravir (EW5GL2X7E0) ; Ritonavir (O3J8G9O825)
    Sprache Englisch
    Erscheinungsdatum 2022-03-24
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.27724
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1320: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: The efficacy and safety of interferons for the treatment of patients with COVID-19

    Afsaneh Noormandi / Mohammad Fathalipour / Reza Daryabeygi-Khotbehsara / Soheil Hassanipour

    Health Technology Assessment in Action, Vol 4, Iss

    protocol for systematic review and meta-analysis of controlled trials

    2021  Band 3

    Abstract: COVID-19 has since been declared a global pandemic by the World Health Organization (WHO), infecting millions worldwide. In the absence of an approved antiviral treatment, several medications are currently being evaluated for their therapeutic ... ...

    Abstract COVID-19 has since been declared a global pandemic by the World Health Organization (WHO), infecting millions worldwide. In the absence of an approved antiviral treatment, several medications are currently being evaluated for their therapeutic effectiveness in the treatment of COVID-19. The use of Interferon (INF) subtypes previously examined in the treatment of SARS and MERS is also being initiated in some clinical trials. Although different clinical trials were evaluated IFNs in the treatment of COVID-19, its safety and efficacy remain unknown. Therefore, this study aims to systematically assess IFNs efficacy and safety in treating patients with COVID-19.
    Schlagwörter - ; Economic biology ; QH705-705.5
    Sprache Englisch
    Erscheinungsdatum 2021-06-01T00:00:00Z
    Verlag Tehran University of Medical Sciences
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  3. Artikel ; Online: Effect of magnesium supplementation on lactate clearance in critically ill patients with severe sepsis: a randomized clinical trial.

    Noormandi, Afsaneh / Khalili, Hossein / Mohammadi, Mostafa / Abdollahi, Alireza

    European journal of clinical pharmacology

    2019  Band 76, Heft 2, Seite(n) 175–184

    Abstract: Objectives: In this study, changes in lactate clearance following magnesium supplementation were evaluated in critically ill patients with severe sepsis.: Methods: Fifty-eight patients with severe sepsis were randomly assigned to receive either ... ...

    Abstract Objectives: In this study, changes in lactate clearance following magnesium supplementation were evaluated in critically ill patients with severe sepsis.
    Methods: Fifty-eight patients with severe sepsis were randomly assigned to receive either magnesium (n = 30) or placebo (n = 28). Patients in the magnesium group received intravenous magnesium sulfate to maintain serum magnesium level around 3 mg/dL for 3 days. The placebo group received the same volume of normal saline. Change in lactate clearance was considered primary outcome of the study.
    Results: Mean increase in the lactate clearance in the magnesium group was significantly higher than the placebo group on day 2 (27.53% vs. 23.79% respectively, p < 0.001) and day 3 (49.83% vs. 37.02% respectively, p < 0.001). Time to lactate clearance was also significantly shorter in the magnesium group than the placebo group (47.28 ± 20.59 vs. 61.20 ± 24.31 h respectively, p = 0.03). Sepsis-related mortality was not significantly different but median length of ICU stay was significantly shorter in the magnesium group than the placebo group (8 vs. 15 days respectively, p < 0.01).
    Conclusions: Magnesium supplementation increased lactate clearance in critically ill patients with severe sepsis. Optimizing serum magnesium level near the upper limit of the normal range may improve severe sepsis outcomes.
    Mesh-Begriff(e) Administration, Intravenous ; Adult ; Critical Illness ; Female ; Humans ; Intensive Care Units/statistics & numerical data ; Lactic Acid/metabolism ; Length of Stay ; Magnesium Sulfate/administration & dosage ; Magnesium Sulfate/blood ; Magnesium Sulfate/pharmacology ; Male ; Middle Aged ; Sepsis/drug therapy ; Sepsis/mortality ; Sepsis/physiopathology ; Treatment Outcome
    Chemische Substanzen Lactic Acid (33X04XA5AT) ; Magnesium Sulfate (7487-88-9)
    Sprache Englisch
    Erscheinungsdatum 2019-12-09
    Erscheinungsland Germany
    Dokumenttyp Journal Article ; Randomized Controlled Trial
    ZDB-ID 121960-1
    ISSN 1432-1041 ; 0031-6970
    ISSN (online) 1432-1041
    ISSN 0031-6970
    DOI 10.1007/s00228-019-02788-w
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 672: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Clinical and economic impacts of clinical pharmacists' interventions in Iran: a systematic review.

    Noormandi, Afsaneh / Karimzadeh, Iman / Mirjalili, Mahtabalsadat / Khalili, Hossein

    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

    2019  Band 27, Heft 1, Seite(n) 361–378

    Abstract: Objectives: There are many studies about Iranian clinical pharmacists' interventions and their impacts on medication safety and cost. The aim of this study is to collect data and critically evaluate the clinical and economic effects of Iranian clinical ... ...

    Abstract Objectives: There are many studies about Iranian clinical pharmacists' interventions and their impacts on medication safety and cost. The aim of this study is to collect data and critically evaluate the clinical and economic effects of Iranian clinical pharmacist interventions and activities. To our best of knowledge, this research is the first review of publications about Iranian clinical pharmacists' interventions and activities.
    Evidence acquisition: Six online databases, including PubMed, Scopus, Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systemic Reviews, and Google Scholar were searched using the terms '"Iranian", "clinical pharmacist", 'adverse drug reactions", "medication errors", "drug interaction", "drug utilization evaluation", "cost", and "interventions" for English studies conducted in Iran and described clinical pharmacist-initiated interventions, published before December 2018. The search and extraction process followed PRISMA guidelines. Observational or retrospective studies, clinical trials, congress abstracts, and case reports or case series were excluded. The search strategy after full-text review identified 39 articles matching the eligibility criteria.
    Results: Thirty-nine articles were recruited. They included establishing pharmaceutical care in out-patient clinics and drug information centers (n = 4); prevention, detection, and management of adverse drug reactions(n = 4), designing protocols and improving drug utilization pattern(n = 16), prevention, detection, and management of medication errors (n = 11), and all clinical pharmacist services(n = 4). Most clinical pharmacist interventions and activities were regarding designing protocols, improving drug utilization pattern, as well as detection, prevention, and management of medication errors. About three-fourth (74.35%) of included studies were from either ambulatory care or in-patient settings in Tehran. The median (interquartile range) duration of intervention as well as follow-up phases was 9 (5) months.
    Conclusion: Data of our review support the beneficial role of clinical pharmacists in the improvement of quality, safety, and efficiency of patients' pharmaceutical care in Iran. Graphical abstract Clinical pharmacists' interventions in Iran.
    Mesh-Begriff(e) Delivery of Health Care, Integrated ; Drug Utilization Review ; Humans ; Iran ; Medication Errors/prevention & control ; Patient Education as Topic/economics ; Patient Education as Topic/methods ; Pharmaceutical Services/economics ; Prescription Drugs/standards ; Professional Role ; Retrospective Studies
    Chemische Substanzen Prescription Drugs
    Sprache Englisch
    Erscheinungsdatum 2019-01-23
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Systematic Review
    ZDB-ID 2129183-4
    ISSN 2008-2231 ; 1560-8115
    ISSN (online) 2008-2231
    ISSN 1560-8115
    DOI 10.1007/s40199-019-00245-8
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel: Comparing the Effects of Melatonin and Zolpidem on Sleep Quality, Depression, and Anxiety in PatientsWithColorectalCancerUndergoingChemotherapy.

    Shahrokhi, Maryam / Ghaeli, Padideh / Arya, Pantea / Shakiba, Alia / Noormandi, Afsaneh / Soleimani, Mehdi / Esfandbod, Mohsen

    Basic and clinical neuroscience

    2021  Band 12, Heft 1, Seite(n) 105–114

    Abstract: Introduction: Patients with cancer may have many complications involving their psychosomatic systems, such as sleep disturbance, depression, and anxiety. Thus, many research studies were conducted to reduce these complications. Zolpidem, as a short-term ...

    Abstract Introduction: Patients with cancer may have many complications involving their psychosomatic systems, such as sleep disturbance, depression, and anxiety. Thus, many research studies were conducted to reduce these complications. Zolpidem, as a short-term non-benzodiazepine treatment of insomnia, and melatonin as a chronobiological functionregulatory hormone, are commonly used for improving sleep quality. This randomized clinical trial aims to compare the effects of zolpidem and melatonin on sleep quality, depression, and anxiety in patients with colorectal cancer.
    Methods: In this single-blinded trial, 90 patients with colorectal cancer undergoing chemotherapy who had obtained a score of 5 or higher on the Pittsburgh Sleep Quality Index (PSQI) were randomly divided into two groups (n=45). One group was treated with 10 mg zolpidem at bedtime, and the other group received 6 mg melatonin at bedtime for 30 days. PSQI on weeks 0, 4, 8, Groningen sleep quality scale, Hamilton rating scale for depression, and Hamilton anxiety rating scale questionnaires were performed to assess patients on weeks 0, 4, and 8. The outcome was then analyzed, and P≤0.05 was considered statistically significant.
    Results: Both zolpidem and melatonin had significant impacts on sleep quality in week 4 (P<0.05). After stopping the treatments, the conditions were noticeably reversed on week 8 (P<0.05). Zolpidem and melatonin were relatively similar in affecting sleep duration, latency, efficiency, and disturbance. None of the two study medications had any considerable influence on anxiety and depression.
    Conclusion: Melatonin and zolpidem are promising agents for treating sleep complications and, to some extent, depression, and anxiety in cancer patients, according to the present study. However, further clinical trials are recommended to confirm the results of this study.
    Sprache Englisch
    Erscheinungsdatum 2021-01-01
    Erscheinungsland Iran
    Dokumenttyp Journal Article
    ZDB-ID 2652444-2
    ISSN 2228-7442 ; 2008-126X
    ISSN (online) 2228-7442
    ISSN 2008-126X
    DOI 10.32598/bcn.12.1.1650.2
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Effects of green tea on Escherichia coli as a uropathogen

    Afsaneh Noormandi / Fatemeh Dabaghzadeh

    Journal of Traditional and Complementary Medicine, Vol 5, Iss 1, Pp 15-

    2015  Band 20

    Abstract: Escherichia coli is the most common cause of urinary tract infections. The development of antibiotic resistance in E. coli is an important problem. Finding alternative antimicrobial agents from plant extracts has received growing interest. Camellia ... ...

    Abstract Escherichia coli is the most common cause of urinary tract infections. The development of antibiotic resistance in E. coli is an important problem. Finding alternative antimicrobial agents from plant extracts has received growing interest. Camellia sinensis is a safe, nontoxic, cheap beverage that has been reported to have antimicrobial effects against various pathogenic bacteria including E. coli. Polyphenolic components of green tea (綠茶 lǜ chá) have antibacterial activity. Catechins also have synergistic effect with antibiotics such as chloramphenicol, amoxicillin, sulfamethoxazole, azithromycin, levofloxacin, gentamycin, methicillin, naldixic acid, and, especially ciprofloxacin. In this review, all experimental studies that evaluated the effect of green tea on E. coli were collected. Data from in vitro studies on the antimicrobial effects of green tea are promising, but human data are currently lacking. In vivo studies on antibacterial effects of green tea and evaluating the efficacy of its catechins in the treatment of urinary tract infection are needed.
    Schlagwörter anti-infective agents ; Camellia sinensis ; catechin ; Escherichia coli ; urinary tract infection ; Medicine ; R
    Sprache Englisch
    Erscheinungsdatum 2015-01-01T00:00:00Z
    Verlag Elsevier
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  7. Artikel ; Online: Potential benefits of zolpidem in disorders of consciousness.

    Noormandi, Afsaneh / Shahrokhi, Maryam / Khalili, Hossein

    Expert review of clinical pharmacology

    2017  Band 10, Heft 9, Seite(n) 983–992

    Abstract: Introduction: It has been suggested that zolpidem may arouse patients with decreased level of consciousness. Zolpidem may partially or even completely reverse abnormal cell metabolism following brain damage. In this article, available evidences ... ...

    Abstract Introduction: It has been suggested that zolpidem may arouse patients with decreased level of consciousness. Zolpidem may partially or even completely reverse abnormal cell metabolism following brain damage. In this article, available evidences regarding effects of zolpidem on disorders of consciousness were reviewed. Areas covered: A literature review was conducted using PubMed, Scopus, Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and Google Scholar as online databases. Search Keywords were 'vegetative state', 'minimally conscious state', 'semi-comatose', 'arousal', 'zolpidem', 'wakefulness', 'awareness', and 'loss of consciousness'. All English language studies that evaluated the effects of zolpidem on disorders of consciousness as a main surrogate endpoint were included. Finally 21 articles within this subject were included. Expert commentary: Zolpidem showed positive effects in several conditions with decreased level of consciousness. However, benefits of zolpidem were not detected in all patients with disorders of consciousness. Patients with post-anoxic encephalopathy or traumatic brain injury did not experience benefits of zolpidem. Available evidences support positive effects of zolpidem on brain functions in patients with non-brain stem injuries.
    Mesh-Begriff(e) Brain Diseases/drug therapy ; Brain Diseases/physiopathology ; Brain Injuries, Traumatic/drug therapy ; Brain Injuries, Traumatic/physiopathology ; Consciousness Disorders/drug therapy ; Consciousness Disorders/physiopathology ; GABA-A Receptor Agonists/pharmacology ; GABA-A Receptor Agonists/therapeutic use ; Humans ; Pyridines/pharmacology ; Pyridines/therapeutic use ; Treatment Outcome
    Chemische Substanzen GABA-A Receptor Agonists ; Pyridines ; zolpidem (7K383OQI23)
    Sprache Englisch
    Erscheinungsdatum 2017-09
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ISSN 1751-2441
    ISSN (online) 1751-2441
    DOI 10.1080/17512433.2017.1347502
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  8. Artikel: Effects of green tea on Escherichia coli as a uropathogen.

    Noormandi, Afsaneh / Dabaghzadeh, Fatemeh

    Journal of traditional and complementary medicine

    2014  Band 5, Heft 1, Seite(n) 15–20

    Abstract: Escherichia coli is the most common cause of urinary tract infections. The development of antibiotic resistance in E. coli is an important problem. Finding alternative antimicrobial agents from plant extracts has received growing interest. Camellia ... ...

    Abstract Escherichia coli is the most common cause of urinary tract infections. The development of antibiotic resistance in E. coli is an important problem. Finding alternative antimicrobial agents from plant extracts has received growing interest. Camellia sinensis is a safe, nontoxic, cheap beverage that has been reported to have antimicrobial effects against various pathogenic bacteria including E. coli. Polyphenolic components of green tea ( lǜ chá) have antibacterial activity. Catechins also have synergistic effect with antibiotics such as chloramphenicol, amoxicillin, sulfamethoxazole, azithromycin, levofloxacin, gentamycin, methicillin, naldixic acid, and, especially ciprofloxacin. In this review, all experimental studies that evaluated the effect of green tea on E. coli were collected. Data from in vitro studies on the antimicrobial effects of green tea are promising, but human data are currently lacking. In vivo studies on antibacterial effects of green tea and evaluating the efficacy of its catechins in the treatment of urinary tract infection are needed.
    Sprache Englisch
    Erscheinungsdatum 2014-12-16
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2709698-1
    ISSN 2225-4110
    ISSN 2225-4110
    DOI 10.1016/j.jtcme.2014.10.005
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang